Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exosomes and Stem Cells program
- Development stage
- Preclinical
- Lead developer
- NurExone Biologic
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal, Intravenous, Intrathecal, Inhalation, Intraarticular, In Situ, Oral
01
Overview
The Exosomes and Stem Cells program is a preclinical-stage combination regenerative therapy being developed through a collaboration between NurExone Biologic and Inteligex. This hybrid therapeutic approach is specifically designed to treat chronic spinal cord injury (SCI) by combining Inteligex's targeted human stem cell platform with NurExone's ExoTherapy exosome-based drug delivery system. The therapy utilizes stem cells to replace key neural cell types lost due to traumatic injury, while simultaneously using exosomes—produced and loaded from the same stem cell line—to deliver regenerative molecular cargo. This dual mechanism aims to provide both structural cell replacement and a supportive biochemical environment to promote neural regeneration. The program is distinct from NurExone's lead candidate, ExoPTEN, which targets acute SCI. The collaboration was announced in October 2023 and has received grant funding from the Israel-Canada bilateral Eureka program.
- Other names
- NurExone-Inteligex Chronic SCI therapyNurExone-Inteligex collaboration programChronic Spinal Cord Injury regenerative therapy
02
Targets
PTEN (Phosphatase and tensin homolog deleted on chromosome ten)
Beyond the preview
Go deeper on Exosomes and Stem Cells program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exosomes and Stem Cells program.